Neoadjuvant tislelizumab combined with disitamab vedotin (RC48) for patients with Her-2 expressing upper tract urothelial carcinoma: A pilot study.

Authors: Houyuan Chen, Hailong Hu, Chong Shen, Yunkai Qie, Zhouliang Wu, Yiduo Bai, Zhe Zhang, Shiwang Huang, Kaipeng Jia, Peng Li, Yuda Lin, Zihan Xue

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16588

Source: Full article

---

Abstract

e16588